---
document_datetime: 2025-12-02 05:36:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-metformin-hydrochloride-accord.html
document_name: sitagliptin-metformin-hydrochloride-accord.html
version: success
processing_time: 0.1105973
conversion_datetime: 2025-12-28 18:51:00.830795
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sitagliptin / Metformin hydrochloride Accord

[RSS](/en/individual-human-medicine.xml/67581)

##### Lapsed

This medicine's authorisation has lapsed

sitagliptin / metformin hydrochloride Medicine Human Lapsed

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sitagliptin / Metformin hydrochloride Accord](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 22 July 2025, the marketing authorisation of Sitagliptin/Metformin Hydrochloride Accord (sitagliptin / metformin hydrochloride) ceased to be valid in the European Union (EU).

The cessation of validity is due to the fact that the marketing authorisation holder, Accord Healthcare S.L.U., had not marketed Sitagliptin/Metformin Hydrochloride Accord in the EU since its initial marketing authorisation. In accordance with provisions of the sunset clause 1 , the marketing authorisation of the medicinal product lapsed as the product had not been marketed in any of the EU Member States within three years of its initial authorisation.

Accord Healthcare S.L.U. confirmed that the product had not been marketed the product due to commercial reasons.

Sitagliptin/Metformin Hydrochloride Accord was granted marketing authorisation in the EU on 22 July 2022 for treatment of type 2 diabetes mellitus.

The marketing authorisation was initially valid for a 5-year period.

Sitagliptin/Metformin Hydrochloride Accord is a generic medicine of Janumet. There are other generic medicinal products of Janumet authorised and marketed in the EU. Sitagliptin/Metformin Hydrochloride Accord is an identical product to Janumet, which is authorised in the EU to treat type 2 diabetes mellitus.

1 Article 14(4) of Regulation (EC) No 726/2004 (\"sunset clause\")

Sitagliptin / Metformin hydrochloride Accord : EPAR - Medicine overview

Reference Number: EMA/382461/2022

English (EN) (176.64 KB - PDF)

**First published:** 03/08/2022

**Last updated:** 13/11/2025

[View](/en/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-108)

български (BG) (207.35 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/bg/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_bg.pdf)

español (ES) (177.48 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/es/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_es.pdf)

čeština (CS) (201.51 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/cs/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_cs.pdf)

dansk (DA) (177.33 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/da/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_da.pdf)

Deutsch (DE) (180.63 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/de/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_de.pdf)

eesti keel (ET) (175.43 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/et/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_et.pdf)

ελληνικά (EL) (210.72 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/el/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_el.pdf)

français (FR) (190.55 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/fr/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_fr.pdf)

hrvatski (HR) (196.42 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/hr/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_hr.pdf)

italiano (IT) (175.75 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/it/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (208.42 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/lv/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (197.7 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/lt/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_lt.pdf)

magyar (HU) (197.85 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/hu/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_hu.pdf)

Malti (MT) (201.77 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/mt/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_mt.pdf)

Nederlands (NL) (178.39 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/nl/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_nl.pdf)

polski (PL) (203.75 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/pl/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_pl.pdf)

português (PT) (177.75 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/pt/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_pt.pdf)

română (RO) (194.78 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/ro/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_ro.pdf)

slovenčina (SK) (200.33 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/sk/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_sk.pdf)

slovenščina (SL) (196.04 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/sl/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_sl.pdf)

Suomi (FI) (174.84 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/fi/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_fi.pdf)

svenska (SV) (175.52 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/sv/documents/overview/sitagliptin-metformin-hydrochloride-accord-epar-medicine-overview_sv.pdf)

Sitagliptin / Metformin hydrochloride Accord : EPAR - Risk-management-plan summary

English (EN) (120.78 KB - PDF)

**First published:** 03/08/2022

**Last updated:** 13/11/2025

[View](/en/documents/rmp-summary/sitagliptin-metformin-hydrochloride-accord-epar-risk-management-plan-summary_en.pdf)

## Product information

Sitagliptin / Metformin hydrochloride Accord : EPAR - Product information

English (EN) (424.39 KB - PDF)

**First published:** 03/08/2022

**Last updated:** 13/11/2025

[View](/en/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-439)

български (BG) (648.93 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/bg/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_bg.pdf)

español (ES) (393.73 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/es/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_es.pdf)

čeština (CS) (445.18 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/cs/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_cs.pdf)

dansk (DA) (433.68 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/da/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_da.pdf)

Deutsch (DE) (493.51 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/de/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_de.pdf)

eesti keel (ET) (407.48 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/et/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_et.pdf)

ελληνικά (EL) (710.51 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/el/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_el.pdf)

français (FR) (470.61 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/fr/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_fr.pdf)

hrvatski (HR) (454.43 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/hr/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_hr.pdf)

íslenska (IS) (296.54 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/is/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_is.pdf)

italiano (IT) (413.69 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/it/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (538.84 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/lv/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (465.17 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/lt/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_lt.pdf)

magyar (HU) (458.41 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/hu/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_hu.pdf)

Malti (MT) (583.46 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/mt/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_mt.pdf)

Nederlands (NL) (452.73 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/nl/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_nl.pdf)

norsk (NO) (397.61 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/no/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_no.pdf)

polski (PL) (515.31 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/pl/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_pl.pdf)

português (PT) (440.8 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/pt/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_pt.pdf)

română (RO) (437.5 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/ro/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_ro.pdf)

slovenčina (SK) (482.27 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/sk/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_sk.pdf)

slovenščina (SL) (422.98 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/sl/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_sl.pdf)

Suomi (FI) (402.87 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/fi/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_fi.pdf)

svenska (SV) (469.82 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/sv/documents/product-information/sitagliptin-metformin-hydrochloride-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** EMA/VR/0000263349 19/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sitagliptin / Metformin hydrochloride Accord : EPAR - All authorised presentations

English (EN) (118.34 KB - PDF)

**First published:** 03/08/2022

**Last updated:** 13/11/2025

[View](/en/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-69)

български (BG) (131.63 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/bg/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (116.71 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/es/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (126.64 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/cs/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (119.97 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/da/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (120.87 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/de/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (122.4 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/et/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (131.36 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/el/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (121.57 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/fr/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (120.07 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/hr/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (125.13 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/is/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (70.17 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/it/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (122.58 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/lv/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (125.31 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/lt/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (151.71 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/hu/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (122.28 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/mt/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (118.6 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/nl/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (119.37 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/no/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (120.52 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/pl/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (119.07 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/pt/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (121.49 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/ro/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (127.77 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/sk/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (122.15 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/sl/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (120.9 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/fi/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (120.47 KB - PDF)

**First published:**

03/08/2022

**Last updated:**

13/11/2025

[View](/sv/documents/all-authorised-presentations/sitagliptin-metformin-hydrochloride-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sitagliptin / Metformin hydrochloride Accord Active substance

- metformin hydrochloride
- sitagliptin hydrochloride monohydrate

International non-proprietary name (INN) or common name

- sitagliptin
- metformin hydrochloride

Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BD07

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

For adult patients with type 2 diabetes mellitus:

- It is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
- It is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
- It is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPAR?) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR? agonist.
- It is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

## Authorisation details

EMA product number EMEA/H/C/005850

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 19/05/2022 Marketing authorisation issued 22/07/2022 Lapse of marketing authorisation 22/07/2025 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sitagliptin / Metformin hydrochloride Accord : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (159.89 KB - PDF)

**First published:** 19/05/2025

**Last updated:** 13/11/2025

[View](/en/documents/procedural-steps-after/sitagliptin-metformin-hydrochloride-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Sitagliptin / Metformin hydrochloride Accord : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (128.58 KB - PDF)

**First published:** 01/09/2022

**Last updated:** 13/11/2025

[View](/en/documents/procedural-steps-after/sitagliptin-metformin-hydrochloride-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Sitagliptin / Metformin hydrochloride Accord : EPAR - Public assessment report

Adopted

Reference Number: EMA/568807/2022

English (EN) (605.42 KB - PDF)

**First published:** 03/08/2022

**Last updated:** 13/11/2025

[View](/en/documents/assessment-report/sitagliptin-metformin-hydrochloride-accord-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sitagliptin / Metformin hydrochloride Accord

Adopted

Reference Number: EMA/264071/2022

English (EN) (183.18 KB - PDF)

**First published:** 20/05/2022

**Last updated:** 13/11/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sitagliptin-metformin-hydrochloride-accord_en.pdf)

#### News on Sitagliptin / Metformin hydrochloride Accord

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022) 20/05/2022

**This page was last updated on** 13/11/2025

## Share this page

[Back to top](#main-content)